Improved referral and survival of newborns after scaling up of intensive care in Suriname

BMC Pediatrics

Table 4 Morbidity of newborns treated at the facility in two time periods

		Period 1 (N = 320) (July 2014–March 2015)		Period 2 (N = 281) (April 2015–December 2015)		Relative Risk (95% CI)	P-value
		N	%	N	%	Relative Risk (95% CI)	P-value
Respiratory morbidity	BPD	4	1.3	10	3.6	2.85 (0.90–8.98)	0.07
	VAP	9	2.8	5	1.8	0.63 (0.21–1.87)	0.41
	Pneumothorax	4	1.3	7	2.5	1.99 (0.59–6.74)	0.27
NEC^a	Total	10	13.5	12	21.4	1.59 (0.74–3.40)	0.24
NEC^a	≥ Stage 2	4	5.4	7	12.5	2.31 (0.71–7.51)	0.16
Sepsis^b	Total	96	30.0	109	38.8	1.29 (1.03–1.62)	0.02
Sepsis^b	Positive blood culture	38	11.9	25	8.9	0.75 (0.46–1.20)	0.24
Positive ESBL culture^c	Total	34	10.6	39	13.9	1.31 (0.85–2.01)	0.22
Duration of stay (days)		Mean	SD	Mean	SD
Duration of stay (days)		13	16	14	18		0.44

BPD bronchopulmonary dysplasia, VAP ventilator-associated pneumonia, NEC necrotizing enterocolitis, ESBL extended spectrum beta-lactamase
^aCalculated for newborns with a birthweight below 1500 g (N = 74 and N = 56 in period 1 and period 2, respectively)
^bIncludes: early and late-onset clinical (i.e., high clinical suspicion, treated with antibiotics for 7 days; raised C-reactive protein levels) and blood culture positive sepsis
^cIncludes: blood and urine cultures and cultures on (tracheal aspirate, skin and anal) swabs, central lines or ventilation tubes

ISSN: 1471-2431